Table 2.

Comparison of rates of genomic alterations between White and Black Veterans.

	SIRE-White		SIRE-Black/AA		P-value (8)	% change (W-B)
	n	% of 1613	n	% of 835
TP53	331	20.52	154	18.44	.2181	2.1
TMPRSS2-ERG	438	27.15	98	11.74	<.0001*	15.4
DDR (1)	219	13.58	95	11.38	.1264	2.2
PTEN/PI3K/AKT	183	11.35	68	8.14	.0138	3.2
AR	137	8.49	61	7.31	.3481	1.2
BRAF	42	2.60	46	5.51	.0005*	−2.9
PTEN	97	6.01	39	4.6	.1925	1.3
CDK12	36	2.23	37	4.43	.0036	−2.2
MMRd (2)	48	2.98	26	3.11	.901	−0.1
ERBB2	31	1.92	20	2.40	.457	−0.5
EGFR	28	1.74	14	1.68	1	0.1
CDKN2A	14	0.87	<11	<1.3	N/A	0.0
FGFR (3)	<11	<0.7	<11	<1.3	N/A	−0.5
IDH1	<12	<0.7	<11	<1.3	N/A	−0.2
PDGFRA	<13	<0.7	<11	<1.3	N/A	0.0
RET	12	0.74	<11	<1.3	N/A	0.5
ROS1	<11	<0.7	<11	<1.3	N/A	−0.2
NTRK (4)	<11	<0.7	<11	<1.3	N/A	0.1
ALK	<11	<0.7	<11	<1.3	N/A	0.1
KIT	13	0.81	<11	<1.3	N/A	0.7
ABL1	<11	<0.7	<11	<1.3	N/A	0.3
Any actionable (5)	463	28.70	213	25.51	.0953	3.2
FDA approved (6)	250	15.50	113	13.53	.2079	2.0
Putative Germline (7)	193	11.97	51	6.11	<.0001*	5.9

(1) DDR: LP/P alteration in ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, CHEK2, FANCA, FANCL, NBN, PALB2, RAD51, RAD51B RAD51C, RAD51D, RAD54L.

(2) MMR deficiency = LP/P alteration in MLH1, MSH2, MSH6, PMS2 and/or MSI-H and/or TMB-H.

(3) FGFR: LP/P alteration in FGFR2, FGFR3.

(4) NTRK: LP/P alteration in NTRK1, NTRK2, NTRK3.

(5) Any actionable: LP/P alteration in DDR, MMRd, ABL1, AKT, BRAF, CDK12, ERBB2, EGFR, IDH1, CDKN2A, NTRK, ALK, FGFR, KIT, PDGFRA, PI3KCA, PTEN, RET, ROS1.

(6) FDA approved: LP/P alteration in MMR deficiency + DDR.

(7) Putative germline = LP/P alteration with VAF>30% in ESMO guideline gene.

(8) *Refers to the Bonferroni corrected value significance level P < .002.